JUN 06, 2019 10:45 AM PDT

Drug Regimen Improves Clinical Outcomes for Kidney Transplant Patients

WRITTEN BY: Nouran Amin

Recent preliminary clinical trial results indicate the immunosuppressive drug belatacept can safely and effectively treat kidney transplant patients without adverse long-term side effects of traditional immunosuppressive regimens. Belatacept was approved by the U.S. Food and Drug Administration in 2011 for the prevention of immune rejection in kidney transplant patients and is the modified form of another drug called abatacept which treats rheumatoid arthritis.

The clinical trial is known as the Belatacept Early Steroid Withdrawal Trial (BEST) represented a significant step forward in enhancing the quality of life for postoperative patients receiving kidney transplantation.

"In the BEST trial, we tried to achieve something that hadn't been done in transplantation: to eliminate the use of corticosteroids very early after surgery and at the same time avoid the toxicities associated with the cornerstone immunosuppressive medications that had been used for four decades," said principal investigator E. Steve Woodle, MD, William A. Altemeier Professor in Research Surgery at the UC College of Medicine and director of Solid Organ Transplantation for UC Health."We wanted to reduce the side effects and toxicities of these medications and make it easier for patients to tolerate their anti-rejection drugs, while achieving rejection rates that are reasonable, this work solved a vexing 40-year-old problem and represents a major step forward in the field of transplantation."

Findings of the two-year study did not utilize the long-term use of prednisone (a corticosteroid) or tacrolimus (a calcineurin inhibitor).

"The primary problem that has prevented elimination of corticosteroids and calcineurin inhibitors to date has been excessive rejection rates," stated Rita Alloway, PharmD, research professor of nephrology at the UC College of Medicine and director of Transplant Clinical Research at UC Health. "The BEST Trial demonstrates that rejection risk with the new belatacept-based regimens was increased somewhat, and the reduced side effects and long-term cardiovascular risk reduction are major potential advantages of these regimens for the future."

Learn more about rejection following transplantation:

The standard care of treatment for patients who receive a kidney transplant is a post-surgery regimen involving corticosteroid and calcineurin inhibitor (CNI) immunosuppressants. These drugs have long been known to help organ transplant patients survive but can result in kidney toxicity or cardiovascular damage.

"This CNI- and steroid-free [immunosuppressive] protocol is a promising step forward in minimizing toxicities and improving renal allograft function," noted the author of the study. "Longer-term observations will need to be continued."

Source: University of Cincinnati

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 15, 2019
Drug Discovery
JUN 15, 2019
Drug Improves Muscle Properties
Currently, adults over 65 are an increasingly growing segment in many countries. In the United States, the elderly population will increase by 40 percent w...
JUN 15, 2019
Drug Discovery
JUN 15, 2019
Drug Combination for Pediatric Low-grade Glioma
Scientists at the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a new drug combination treatment ta...
JUN 15, 2019
Drug Discovery
JUN 15, 2019
Chemopreventative Drug Targets H. Pylori Infections
A chemopreventative drug being tested for its ability to inhibit the production of cell growth in multiple types of cancer was found to act directly on the...
JUN 15, 2019
Drug Discovery
JUN 15, 2019
Type 2 Diabetic Drug Reverses Heart Failure
In a study published in the Journal of American Cardiology, a drug used for the treatment of diabetes—empagliflozin—was shown to improve the he...
JUN 15, 2019
Drug Discovery
JUN 15, 2019
Self-Inflating Capsule To Tackle Obesity
A team of collaborative researchers have developed a self-inflating weight management capsule used for the treatment of obesity called the EndoPil. The &ls...
JUN 15, 2019
Drug Discovery
JUN 15, 2019
Novel Treatments for Auto-immune Disorders
A recent research study examined a library of almost 300,000 small molecules to search for a molecule that may be a potential target for the human GMP-AMP ...
Loading Comments...